Two case reports showed that one patient with RET fusion positive NSCLC and ten patients with RET-mutated medullary thyroid carcinoma treated with selpercatinib experienced intestinal edema [129,130]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.